ArticleThe Laryngoscope2026
Implementation of a Novel VTE Risk Assessment and Prophylaxis Strategy for Otolaryngology Surgery.
Article in The Laryngoscope, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Implementation of a Novel VTE Risk Assessment and Prophylaxis Strategy for Otolaryngology Surgery.The Laryngoscope · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the feasibility, process adherence, and clinical outcomes associated with department-wide implementation of simplified venous thromboembolism (VTE) risk assessment models (RAM) for inpatient and ambulatory otolaryngology surgical patients.
methodsA mixed prospective and retrospective quality improvement initiative was conducted across two tertiary academic medical centers, including all scheduled adult otolaryngology surgical procedures from January 3, 2025, to November 20, 2025. Inpatient admissions were risk stratified using the COBRA score and ambulatory procedures using the Pannucci-NSQIP score; inpatient risk stratifications were shared with surgeons. High VTE risk was defined as COBRA ≥ 4 for inpatients and Pannucci-NSQIP ≥ 4 for ambulatory cases. Pharmacologic prophylaxis beginning on postoperative Day 1 was recommended for high-risk inpatients. Process measures included adherence to prophylaxis guidance and documented rationales for deviation. Outcome measures included 30-day VTE and hemorrhage events.
resultsA total of 3854 consecutive adult procedures were included (608 inpatient, 3246 ambulatory). 65% of inpatients and 14% of ambulatory cases were classified as high risk. Among high-risk inpatients with length of stay ≥ 2 days, VTE occurred in 2.5% of patients receiving chemoprophylaxis on POD1 compared with 4.7% of those not receiving POD1 prophylaxis. No VTE events occurred in low-risk inpatients, high-risk inpatients discharged on POD1, or high-risk ambulatory patients. Hemorrhage rates were similar across prophylaxis groups (3.2%-4.1%). Overall VTE rates were 1.8% for inpatients and 0.1% for ambulatory procedures.
conclusionThe simplified COBRA and Pannucci-NSQIP RAMs provide a feasible and potentially scalable framework for integrating VTE risk stratification into routine otolaryngology practice. LEVEL OF EVIDENCE: 3:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.